Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockValiant Organics Ltd (VALIANTORG) is currently trading at 221.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Valiant Organics Limited manufactures benzene-based specialty chemicals and is one of the world’s largest producers of chlorophenol derivatives and a leading domestic producer of PNA, anisidines and PAP, supplying dyes, pigments, agrochemicals, pharmaceuticals and specialty chemical customers from six manufacturing units located strategically near western Indian ports, with an aggregate installed capacity of approximately 70,000 MTPA and five Zero Liquid Discharge plants. Financial performance shows a meaningful recovery: 9M-FY26 consolidated revenue was INR 5,210 million (up ~1.2% YoY) while EBITDA expanded to INR 616 million with an 11.82% margin, driven by improved gross margin, cost control and an exceptional insurance refund of INR 57 million; cumulative results mark a PAT turnaround to INR 175 million after prior year losses, indicating operational resilience and margin restoration. The business is product- and industry-diversified but concentrated in dyes & pigments (52% of FY25 revenue) with hydrogenation chemistry contributing the largest share; Valiant’s integrated, multi-chemistry plants and in-house process knowledge enable production of differentiated intermediates such as PCP, OCP, PNA, ONA, PAP and IPPCA, positioning the company to substitute imports and serve clients requiring technical specifications and multi-step chemistries. Operational indicators show volatile quarterly trends: Q3-FY26 revenue dipped 14.8% YoY to INR 1,593 million with EBITDA margin at 9.79%, while sales volumes shifted across chemistries (notably higher ammonolysis volumes); the balance sheet retains manageable leverage (Net Debt/Equity ~0.31 in H1-FY26) and finance costs declined ~22% YoY, supporting earnings recovery and incremental cash flow from operations. Strategic risks and catalysts are visible: near-term pricing pressure and demand softness affected Q3, but continued focus on higher-margin pharma intermediates, port-proximate manufacturing, ZLD compliance and recent plant commissions provide a pathway to sustained margin improvement; market capitalization stood at ~INR 7,684 million as of December 31, 2025, with promoters retaining meaningful stake and public float providing liquidity.
Over the past 52 weeks, Valiant Organics Ltd has traded between a low of ₹210.05 and a high of ₹508.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Valiant Organics Ltd has a market capitalization of approximately 628.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Valiant Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.31 and operates in the Chemicals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 628.06 Cr, Valiant Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Valiant Organics Ltd operates in the Chemicals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Valiant Organics Ltd is 29.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
105.90 | 769 Cr | 10.87 | 2.13 | 0.47 | 19.46 | 17.49 | 9.72 | |
606.35 | 769 Cr | 312.00 | 2.61 | 1.27 | 2.06 | 3.46 | 0.63 | |
227.65 | 628 Cr | 29.31 | 0.85 | 0.00 | 3.18 | 5.34 | 1.87 | |
174.20 | 523 Cr | 11.82 | 0.89 | 1.44 | 8.74 | 10.93 | 4.51 | |
520.00 | 477 Cr | 27.47 | 1.11 | 0.58 | 4.05 | 5.79 | 2.76 | |
140.45 | 365 Cr | 11.27 | 0.84 | 1.78 | 7.50 | 9.65 | 6.16 | |
385.65 | 327 Cr | 18.27 | 1.38 | 0.26 | 6.34 | 9.04 | 3.65 |
Bearish
4
Neutral
2
Bullish
8
Bearish
36
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Valiant Organics Limited manufactures benzene-based specialty chemicals and is one of the world’s largest producers of chlorophenol derivatives and a leading domestic producer of PNA, anisidines and PAP, supplying dyes, pigments, agrochemicals, pharmaceuticals and specialty chemical customers from six manufacturing units located strategically near western Indian ports, with an aggregate installed capacity of approximately 70,000 MTPA and five Zero Liquid Discharge plants.
Financial performance shows a meaningful recovery: 9M-FY26 consolidated revenue was INR 5,210 million (up ~1.2% YoY) while EBITDA expanded to INR 616 million with an 11.82% margin, driven by improved gross margin, cost control and an exceptional insurance refund of INR 57 million; cumulative results mark a PAT turnaround to INR 175 million after prior year losses, indicating operational resilience and margin restoration.
The business is product- and industry-diversified but concentrated in dyes & pigments (52% of FY25 revenue) with hydrogenation chemistry contributing the largest share; Valiant’s integrated, multi-chemistry plants and in-house process knowledge enable production of differentiated intermediates such as PCP, OCP, PNA, ONA, PAP and IPPCA, positioning the company to substitute imports and serve clients requiring technical specifications and multi-step chemistries.
Operational indicators show volatile quarterly trends: Q3-FY26 revenue dipped 14.8% YoY to INR 1,593 million with EBITDA margin at 9.79%, while sales volumes shifted across chemistries (notably higher ammonolysis volumes); the balance sheet retains manageable leverage (Net Debt/Equity ~0.31 in H1-FY26) and finance costs declined ~22% YoY, supporting earnings recovery and incremental cash flow from operations.
Strategic risks and catalysts are visible: near-term pricing pressure and demand softness affected Q3, but continued focus on higher-margin pharma intermediates, port-proximate manufacturing, ZLD compliance and recent plant commissions provide a pathway to sustained margin improvement; market capitalization stood at ~INR 7,684 million as of December 31, 2025, with promoters retaining meaningful stake and public float providing liquidity.
Chemicals
Chemicals - Speciality - Large
628 Cr
Moderate Risk
29.3
43.3
0.5
0.9
508.30
217.00
Sales CAGR
Profit CAGR
ROE
ROCE
